No Data
No Data
Zai Lab Limited (NASDAQ:ZLAB) Institutional Owners May Be Pleased With Recent Gains After 25% Loss Over the Past Year
Zai Lab Limited's (NASDAQ:ZLAB) Prospects Need A Boost To Lift Shares
Zai Lab Limited to Approve Interim Financial Results
ZAI LAB: Notice of Audit Committee Action
Brokerage Focus: China Securities Co., Ltd. maintains a "buy" rating on Zai Lab (09688), pointing to high revenue growth in the second quarter and better-than-expected performance of Ai Ji Mo De.
China Securities Co., Ltd. released a research report, stating that Zai Lab (09688) announced its Q2 2024 performance. Q2 24 product revenue was $0.1001 billion, a year-on-year increase of 45%. The net loss was $80.3 million, a year-on-year decrease of 33.6%. The bank said that all five products currently listed by the company have achieved sales revenue, and among them, IGM's growth momentum is strong. The annual sales guidance has been raised to over $80 million. The bank believes that with the approval of several new products and indications in the next two to three years, revenue will grow rapidly, and through revenue growth and adequate funding, the company will be able to achieve sustainable development.
BofA Securities Maintains Zai Lab(ZLAB.US) With Buy Rating, Announces Target Price $25
No Data